Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25375944 | 0.95 | MAOB (0.36) | HTR2ASLC6A2SLC6A4SLC6A3MLYCD | |
| SCHEMBL25375514 | 0.91 | HTR2A (0.34) | HTR2ASLC6A2SLC6A4SLC6A3MLYCD | |
| SCHEMBL25378916 | 0.87 | HTR2A (0.36) | HTR2A | |
| SCHEMBL25373869 | 0.85 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3MLYCDF2 | |
| SCHEMBL25375229 | 0.83 | PTGDR2 (0.35) | HTR2ASLC6A2SLC6A4 | |
| SCHEMBL25376017 | 0.83 | ALDH1A1 (0.41) | HTR2A | |
| SCHEMBL25378564 | 0.81 | SLC6A2 (0.42) | SLC6A2SLC6A3MLYCD | |
| SCHEMBL25377812 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3MLYCDF2 | |
| SCHEMBL25377064 | 0.80 | P2RX7 (0.33) | HTR2A | |
| SCHEMBL25379773 | 0.80 | MAOB (0.39) | HTR2ASLC6A2SLC6A4SLC6A3MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | HTR2A 1255/4885SLC6A2 4144/4885SLC6A4 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.